There are 702 resources available
175P - Tislelizumab plus hepatic arterial infusion chemotherapy (HAIC) for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT): A prospective, signal-arm, phase II clinical study
Presenter: HAIBIN ZHANG
Session: Poster Display session
176P - Liver pharmacodynamics in an open-label phase Ib/IIa study of fostroxacitabine bralpamide (fostrox, MIV-818) in combination with lenvatinib in 2L/3L hepatocellular carcinoma
Presenter: Hong Jae Chon
Session: Poster Display session
177P - Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A meta-analysis and systematic review
Presenter: Wei Zhang
Session: Poster Display session
178P - Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: An updated meta-analysis and meta-regression of observational studies
Presenter: Mahmoud Abdelgalil
Session: Poster Display session
179P - Transarterial chemoembolization plus lenvatinib with or without immune checkpoint inhibitors for advanced hepatocellular carcinoma: A meta-analysis and systematic review
Presenter: Wei Zhang
Session: Poster Display session
180P - A systematic review with meta-analysis of risks and benefits of tyrosine kinase inhibitors in hepatocellular carcinoma treatment
Presenter: Jennifer Martínez-Geijo
Session: Poster Display session
181P - Circulating tumor DNA (ctDNA) testing for recurrence and treatment response monitoring in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster Display session
182P - A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe
Presenter: Federico Rossari
Session: Poster Display session
183P - Lenvatinib versus sorafenib for recurrence of hepatocellular carcinoma after liver transplantation
Presenter: Gonzalo Sapisochin
Session: Poster Display session
184P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)
Presenter: Silvia Camera
Session: Poster Display session